Event

Simple Transfusion vs. Exchange Transfusion and Future Therapies in Patients with Sickle Cell Disease (21EL-674)

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Wednesday, September 15, 2021 - On-Demand Available

Program Number: 21EL-674

  • Educational Track: Technical/Clinical
  • Topics: Apheresis, Cellular Therapy, Collection, Complications, Inventory, Management Operations, Outcomes, Outcomes/Engagement, Patient Blood Management, Patient Transfusion, Special Patients and Situations, Therapeutic Apheresis, Therapeutic Goals, Transfusion Process, Transfusion Safety
  • Intended Audience: Directors, Hospital Blood Banks, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
  • Teaching Level: Advanced, Intermediate
  • Director/Moderator: Huy P. Pham, MD, MPH, Medical Director, National Marrow Donor Program (NMDP), Seattle, WA
    Speakers:

    • Patricia A. Shi, MD, Medical Director, New York Blood Center, New York, NY
    • Ross Fasano, MD, Associate Professor, Emory University, Atlanta, GA
    • Monika Paroder, MD, PhD, Assistant Professor, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
  • Program Description

    Sickle cell disease is affected approximately 100,000 people in the United States. It is a major public health concern and the patients have a significant morbidity and mortality. At this time, transfusion of red blood cells (RBCs) is one of the main treatment strategies for this disease. However, transfusion is potentially associated with multiple complications, including transfusion-transmitted infections and alloimmunizations. 

    Given that there are few quality studies investigated the effect of simple vs. exchange transfusion in patients with sickle cell disease, this program will summarize the current data and expert opinion on the use of each treatment modality. Key considerations that physicians should be aware of when choosing between treatment options as well as challenges in pediatric patients will also be addressed. Lastly, novel therapies in the treatment of sickle cell disease, including cellular therapies, will be discussed.

    Learning Objectives

    After participating in this educational activity, participants should be able to:

    • Discuss considerations for simple vs. exchange transfusions in patients with sickle cell disease.
    • Summarize key considerations in using different treatment options in pediatric patients.
    • Describe current novel therapies, including cellular therapies, as treatment modalities in sickle cell disease.

    Registration

    Please note: If you registered for the live eCast you do not need to register for the on-demand eCast (access to the on-demand eCast was included with the live eCast registration).

    Single Viewer Register
    Group Viewing Register

    Continuing Education Credit

    AABB designates both the live and on-demand version of this eCast each to be eligible for 1.5 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.

    Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.

    Speaker Biographies

    Dr. Ross Fasano is an Associate Professor of Pathology and Laboratory Medicine and Pediatric Hematology/Oncology at Emory University School of Medicine. He also has an adjunct appointment in Adult Hematology and provides comprehensive care to adult patients with sickle cell disease at Grady Memorial Hospital. His clinical expertise is in pediatric transfusion and hematology, with an emphasis on chronic transfusion therapy for children and adults with sickle cell disease.

    Dr. Monika Paroder is an Associate Director of Transfusion Medicine at Montefiore Medical Center, which treats a large sickle cell patient population. She received her MD/PhD from the Albert Einstein College of Medicine and completed her residency and fellowship training at New York Presbyterian – Columbia University Medical Center and the New York Blood Center.

    Dr. Patricia Shi has taken care of patients with sickle cell disease as an apheresis director and adult hematologist at Mount Sinai and New York Blood Center. She received her MD at Duke and her fellowship training at NIH and Johns Hopkins.